MHRA paediatric investigation plan
Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein)
MHRA paediatric investigation plan MHRA-100470-PIP01-22-M01 (update) · Modification
Key facts
| PIP number | MHRA-100470-PIP01-22-M01 (update) |
|---|---|
| Active substances | Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein, Neisseria meningitidis serogroup B fHbp subfamily A, Neisseria meningitidis serogroup B fHbp subfamily B, Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid carrier protein, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid carrier protein, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid carrier protein |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of Invasive disease caused by Neisseria meningitidis group A, B, C, W and Y |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Published | Dec 19, 2023 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: